Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2862 Concurrent Metastatic Pulmonary Neuroendocrine Tumor and Pituitary Macroadenoma

Introduction: The coexistence of a sellar mass in a patient with a neuroendocrine tumor, while rare, can paint the clinical picture of either a genetic syndrome, most notably multiple endocrine neoplasia syndrome type 1(MEN1) or pituitary metastasis recently more frequent probably due to the longer survival of cancer patients.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Martin C, Mitrache M, Nitipir C, Terzea D, Stroescu C,

Keywords: pulmonary neuroendocrine tumors, pituitary macroadenoma,

#1910 Acute Somatostatin Analog Suppression Test in a Patient with Thyrotropin-secreting Pituitary Macroadenoma

Introduction: Thyrotropin-secreting pituitary adenomas are rare and often plurihormonal tumours. The long-acting somatostatin analogues (SSA) are effective in cases not cured after surgery.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Trifanescu R, Smarandoiu A, Baciu I, Dumitrascu A, Terzea D,

Keywords: octreotide, thyrotropinoma,

#80 Metastatic growth hormone secreting pituitary carcinoma treated with peptide receptor radionuclide therapy

Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Kassem S

Authors: Kassem S, Gross D, Doviner V, Dresner-Pollak R,

Keywords: pituitary carcinoma, peptide receptor radionuclide therapy, acromegaly,